When life sciences meets AI: How Graph AI is redefining global drug safety
Bessemer Venture Partners leads Graph AI’s seed round, backing the team poised to disrupt an $8 billion pharmacovigilance market
The $1.4 trillion global IT services industry is in the midst of a once-in-a-generation transformation. With AI’s ability to perform deep reasoning across large, unstructured datasets and synthesize multimodal information, many repetitive, moderate complexity tasks can now be executed better, faster, and cheaper through AI-native products — with more consistency than humans.
One domain, in particular, ripe for disruption is the $8 billion pharmacovigilance market: a critical component of global drug regulation safety. Regulatory authorities require pharmaceutical companies to continuously monitor, detect, and report adverse drug events (ADEs) throughout a drug’s lifecycle, from trials to post-market use. Historically, pharmaceutical companies have outsourced this work to large service firms that employ vast teams who manually review call-center logs, legal filings, medical literature, emails, and social-media data to identify ADEs, determine causality, and prepare regulatory submissions. This process is fragmented, reactive, and heavily human-dependent — leading to inefficiencies, compliance risk, and potential brand damage.
Graph AI is redefining this workflow through its flagship product, Graph Safety. Using context-aware AI and intelligent automation, the platform delivers a comprehensive, end-to-end pharmacovigilance solution globally. Already live with enterprise customers, Graph will automate ADE case processing, signal detection, aggregate reporting, and compliance. The result is a shift from manual, error-prone operations to AI-driven workflows that augment medical reviewers, improve accuracy, and dramatically shorten reporting cycles. Enterprise customers have reported up to 70% efficiency gains, 90% faster regulatory reporting, and substantial cost savings, all while maintaining end-to-end traceability and audit readiness globally.
At Bessemer, we believe Graph’s journey reflects a larger shift unfolding across industries, where AI transforms not only how work gets done but how impact is delivered. In the AI era, our dedication to finding and backing the top vertical software innovators who can harness this groundbreaking technology is stronger than ever.
Founders Raghavendra Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO) are industry veterans with vast experience leading global organizations, including LTI Mindtree, Infosys, ServiceNow, Google, and Cisco. We believe their rare blend of expertise in technology, outsourcing, and enterprise operations uniquely positions them to build a new class of AI-first, product-driven patient safety platform that transforms this services-driven industry. We’re excited to lead their seed round to support them in harnessing AI to make pharmaceutical drugs safer for the world.
